Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.
Open accessThe DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double-blind trial. End points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands were defined: treatment policy (effect regardless of trial product discontinuation or rescue medication) and trial product (effect assuming trial product continuation without rescue medication) in randomized patients. RESULTS: Oral semaglutide was superior to placebo in reducing HbA1c (estimated treatment difference [ETD] –0.5% [95% CI –0.7, –0.3], –0.9% [–1.1, –0.7], and –1.2% [–1.4, –1.0] for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD −0.9 kg [95% CI −1.8, −0.0], −2.0 kg [−3.0, −1.0], and −3.3 kg [−4.2, −2.3]; P = 0.0392 for 3 mg, P ≤ 0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater dose-dependent HbA1c and body weight reductions versus placebo were achieved with oral semaglutide at weeks 26 and 52 (both estimands). The most frequent adverse event with oral semaglutide was nausea (11.4–23.2% of patients vs. 7.1% with placebo; mostly mild to moderate). CONCLUSIONS: Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In other phase 3 trials, no increase in hypoglycemia risk was observed versus comparator groups, including other GLP-1RAs (18–21, 23, 33–36).”
From Safety of Semaglutide (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When added to basal insulin, selective glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated improved glycemic control and body weight loss without increasing the risk of hypoglycemia and reducing insulin requirements.[2][3][4][5][6]”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationStatistical Analysis with Missing Data
Bo., N., Little, R. J. A., & Rubin, D. B. (1988) · Population (French Edition) · doi:10.2307/1533221 · Cited by 2,095
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · cited 1×
“Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce HbA1c with a low risk of hypoglycemia and favorable effects on body weight (1,2).”
BackgroundSelf-citationPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Self-citationStatistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553 · cited 2×
“hydroxybenzoyl] amino) caprylate,which facilitates semaglutide absorption across the gastric mucosa (10).”
BackgroundDavies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506 · cited 1×
“Consistent with other semaglutide trials (6,13,19,30), no unexpected safety issues were identified.”
ResultAroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
Self-citationGoto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0883 · Cited by 463
Self-citationRosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421
Self-citationHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416 · cited 2×
“disorders, specifically nausea, were the most frequentAEswithoral semaglutide, which is consistent with other GLP-1RAs, and nausea is a known class effect of these agents (1).”
BackgroundSemaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412 · cited 3×
“subcutaneous, once-weekly formulation improved glycemic control and reduced body weight from baseline when used alongside basal insulin in patients with type 2 diabetes (6).”
BackgroundResultSelf-citationBuse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259
Self-citationLiu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180 · cited 1×
“Insulin use is also associated with an increased risk of hypoglycemia (24,25), which could be overcome by adding a GLP-1RA.”
BackgroundBretz, F., Posch, M., Glimm, E., Klinglmueller, F., Maurer, W., & Rohmeyer, K. (2011) · Biometrical Journal · doi:10.1002/bimj.201000239 · Cited by 172 · cited 1×
“The confirmation of efficacy of oral semaglutide on change in HbA1c and body weight, both from baseline to week 26, was based on a weighted Bonferroni closed-testing strategy (15) (outlined in Supplementary Appendix 5) to control the overall type I error for the hypotheses evaluated by the treatment policy estimand.”
MethodAddressing barriers to initiation of insulin in patients with type 2 diabetes
Peyrot, M. F., Rubin, R. R., & Khunti, K. (2010) · Primary care diabetes · doi:10.1016/s1751-9918(10)60004-6 · Cited by 142 · cited 1×
“cationofan insulin regimen(21,22), suchas weight gain (23).”
Pozzilli, P., Norwood, P., Jódar, E., Davies, M. J., Ivanyi, T., Jiang, H., Woodward, D. B., & Milicevic, Z. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12937 · Cited by 137
Self-citationAhmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., de Loredo, L., Tornøe, K., Boopalan, A., Nauck, M. A., & on behalf of the NN2211‐3917 Study Group (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12539 · Cited by 104
Castellana, M., Cignarelli, A., Brescia, F., Laviola, L., & Giorgino, F. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3082 · Cited by 84
International Council for Harmonization
Dhandia, D., Jain, S., Shukla, V. K., Sharma, N., Yadav, P., & Arora, S. (2025) · Understanding Pharmaceutical Standards and Regulations · doi:10.4324/9781003500971-15 · Cited by 75
Self-citationAroda, V. R., Saugstrup, T., Buse, J. B., Donsmark, M., Zacho, J., & Davies, M. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13804 · Cited by 71 · cited 1×
“Both estimands were defined based on interactions with regulatory agencies (11).”
BackgroundSelf-citationBAJAJ, H. S., Venn, K., Ye, C., Patrick, A., Kalra, S., Khandwala, H. M., Aslam, N., Twum-Barima, D., & Aronson, R. (2016) · Diabetes Care · doi:10.2337/dc16-1582 · Cited by 65 · cited 1×
“This would be expected from a regimen with a prandial component, and an association between hypoglycemia and bolus insulin has previously been reported (27,28).”
Self-citationEfficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
Erpeldinger, S., Rehman, M., Berkhout, C., Pigache, C., Zerbib, Y., Regnault, F., Guérin, E., Supper, I., Cornu, C., Kassai, B., et al. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0120-z · Cited by 53 · cited 1×
“Insulin use is also associated with an increased risk of hypoglycemia (24,25), which could be overcome by adding a GLP-1RA.”
BackgroundMehrotra, D. V. (2019) · Clinical Trials · doi:10.1177/1740774519844259 · Cited by 44
Treating psychological insulin resistance in type 2 diabetes
Allen, N. A., Zagarins, S., Feinberg, R. G., & Welch, G. W. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.11.005 · Cited by 27 · cited 1×
“cationofan insulin regimen(21,22), suchas weight gain (23).”
Improving treatment success rates for type 2 diabetes: recommendations for a changing environment.
Triplitt, C. L. (2010) · PubMed · Cited by 25
Porcellati, F., Lucidi, P., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30004-0 · Cited by 22
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
“When added to basal insulin, selective glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated improved glycemic control and body weight loss without increasing the risk of hypoglycemia and reducing insulin requirements.(2-6)Glucose-dependent insulinotropic polypeptide is the primary incretin hormone respo…”
BackgroundResultSelf-citationSmits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001952 · Cited by 240
Metadata
- Authors
- Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, Zinman, B., Fikry, S., Bajaj, H., Landry, D., Caplan, D., Woo, V., Harris, S., Thuan, J.-F., Serusclat, P., Cariou, B., Gourdy, P., Fradet, G., Monier, A., Borot, S., Monguillon, P., Gouet, D., Doupis, J., Tentolouris, N., Tsimichodimos, V., Melidonis, A., Bekiari, E., Bargiota, A., Agarwal, S., Saboo, B., Chatterjee, S., Mohan, V., Shaikh, S., Gupta, Y., Bhattacharyya, A., Manikath, N., Jain, S., Sasaki, T., Osonoi, T., Fukuda, S., Wada, S., Kiyosue, A., Ide, Y., Onishi, Y., Matoba, K., Takai, K., Yamauchi, A., Inoue, S., Kaneko, S., Ikeda, H., Ohta, Y., Hisatomi, A., Senokuchi, T., Jinnouchi, H., Nakamura, S., Soto, J. R. L., Briones, I. R., Bogdanski, P., Szyprowska, E., Modzelewska, A., Wozniak, I., Zyangirova, S., Sergeeva-Kondrachenko, M., Davis, T., Thomson, S., Frias, J., Gandy, W., Lingvay, I., Pounds, K., Bowman-Stroud, C., Dempsey, M., Huffman, D., Ahmed, A., Fraser, N., Ortiz-Carrasquillo, R., Bolster, D. E., Adams, M., Hummel, M., Free, A., Houser, P., Shockey, G., Barnum, O., Bhasker, K., Cornett, G., Streja, D., Kirby, W., Lynd, S., Folkerth, S., Nakhle, S., Norwood, P., Perez, R., Snyder, B., Farris, N., Litchfield, W., Hamdy, O., Park, J., Aroda, V., & Buse, J.
- Affiliations
- Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- University of North Carolina at Chapel Hill (US)
- Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Kumamoto University (JP)
- ORCID
- Aroda, Vanita R.
- Buse, John B.
- Harris, Stewart B.
- Araki, Eiichi
- Bajaj, Harpreet
- Woo, Vincent
- Gourdy, Pierre
- Borot, Sophie
- Bekiari, Eleni
- Saboo, Banshi
- Chatterjee, Sanjay
- Mohan, Viswanathan
- Shaikh, Shehla
- Gupta, Yashdeep
- Bhattacharyya, Arpandev
- Sasaki, Takashi
- Osonoi, Takeshi
- Kiyosue, Arihiro
- Onishi, Yukiko
- Kaneko, Shizuka
- Ikeda, Hiroki
- Ohta, Yasuharu
- Senokuchi, Takafumi
- Jinnouchi, Hideaki
- Nakamura, Shuji
- Lingvay, Ildiko
- Norwood, Paul
- Hamdy, Osama
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-07-10
- Volume
- 42
- Issue
- 12
- Pages
- 2262-2271
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7364672
- OpenAlex
- W2974714926
- Semantic Scholar
- dfcdee292cee0de5fee471e8d85a78bf385a1d29
- Cited by
- 300
- References
- 37
- Citations by year
- 2026: 28 · 2025: 62 · 2024: 51 · 2023: 32 · 2022: 39 · 2021: 43 · 2020: 41 · 2019: 3
- FWCI
- 25.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Diabetes Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- CSL Behring
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- MannKind Corporation
- Kowa Company
- Zafgen
- Boehringer Ingelheim Japan
- Eisai
- Novo Nordisk (U54-DK-118612, UC4-DK-108612, UL1-TR-002489)
- Astellas Pharma
- Shionogi
- Terumo
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- National Institutes of Health (UL1TR002489, UL1-TR-)
- Japan Society for the Promotion of Science (17H04201, 18K08482)
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK108612, U01DK098246, U54DK118612)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, insulin, metformin, glycemic control, HbA1c, weight loss, nausea, GLP-1 receptor agonists, treatment policy estimand, dose-dependent effects, uncontrolled diabetes, adverse events, tolerability, rescue medication, treatment discontinuation
- MeSH terms
- Semaglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Nausea, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.